Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands

Article abstract of DOI:10.3390/molecules18010154

Novel conformationally restricted analogues of agomelatine were synthesized and pharmacologically evaluated at MT1 and MT2 melatoninergic receptors. Replacement of the N-Acetyl side chain of agomelatine by oxathiadiazole-2-oxide (compound 3), oxadiazole-5(4H)-one (compound 4), tetrazole (compound 5), oxazolidinone (compound 7a), pyrrolidinone (compound 7b), imidazolidinedione (compound 12), thiazole (compounds 13 and 14) and isoxazole moieties (compound 15) led to a decrease of the melatoninergic binding affinities, particularly at MT₁. Compounds 7a and 7b exhibiting nanomolar affinity towards the MT2 receptors subtypes have shown the most interesting pharmacological results of this series with the appearance of a weak MT₂-selectivity.

Full text of DOI:10.3390/molecules18010154

Molecules 2013, 18, 154-166; doi:10.3390/molecules18010154
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Novel Conformationally Constrained Analogues of Agomelatine
as New Melatoninergic Ligands
Marouan Rami 1,2,*, Elodie Landagaray 1,2, Mohamed Ettaoussi 1,2, Koussayla Boukhalfa 1,2
Daniel-Henri Caignard 3, Philippe Delagrange 3, Pascal Berthelot 1,2 and Saïd Yous 1,2
,
1
University of Lille Nord de France, F-59000 Lille, France
2
UDSL, EA GRIIOT, UFR Pharmacie, F-59000 Lille, France
3
Département des Sciences Expérimentales, Institut de Recherches Servier, 92150 Suresnes, France
* Author to whom correspondence should be addressed; E-Mail: marouanr@yahoo.fr;
Tel.: +33-3-2096-4255; Fax: +33-3-2096-4913.
Received: 29 October 2012; in revised form: 14 December 2012 / Accepted: 18 December 2012 /
Published: 24 December 2012
Abstract: Novel conformationally restricted analogues of agomelatine were synthesized
and pharmacologically evaluated at MT1 and MT2 melatoninergic receptors. Replacement of
the N-acetyl side chain of agomelatine by oxathiadiazole-2-oxide (compound 3),
oxadiazole-5(4H)-one (compound 4), tetrazole (compound 5), oxazolidinone (compound
7a), pyrrolidinone (compound 7b), imidazolidinedione (compound 12), thiazole
(compounds 13 and 14) and isoxazole moieties (compound 15) led to a decrease of the
melatoninergic binding affinities, particularly at MT1. Compounds 7a and 7b exhibiting
nanomolar affinity towards the MT2 receptors subtypes have shown the most interesting
pharmacological results of this series with the appearance of a weak MT2-selectivity.
Keywords: agomelatine; agonist; conformationally restriction; melatonin
1. Introduction
Melatonin or N-acetyl-5-methoxytryptamine (Figure 1), is a neurohormone that is synthesized and
secreted from the pineal gland during the period of darkness following a circadian rhythm [1]. Since the
demonstration of its role in many physiological processes such as the regulation of immune functions [2],
retinal physiology [3], circadian and seasonal rhythms [4] research efforts to identify new melatoninergic

Molecules 2013, 18
155
ligands grow up continuously. However, much more efforts must be done to clarify the various functions
exerted by melatonin and its mechanisms of action.
This neurohormone exerts its multiple pharmacological actions through two G-protein-coupled
receptors MT1 and MT2 which were cloned in the mid-1990s [2–5]. A third melatonin binding site, MT3,
having lower affinity than MT1 and MT2 has been characterized as the hamster homologue of quinone
reductase 2 (QR2 EC 1.6.99.2) [6]. Exploring the exact physiological role of each of these binding sites
requires selective MT1, MT2 and MT3 ligands. Melatoninergic MT1 receptors are expressed in several
areas of the brain in particular in the suprachiasmatic nuclei (SCN) and the pars tuberalis. The MT2
receptors are localized in the SCN and retina. The low affinity binding site, MT3 is closely related to the
detoxifying enzyme quinone reductase 2 and its exact biological relevance in melatonin’s effects is still
uncertain [7]. Nonetheless, MT3 has shown to be involved in acute inflammatory responses in the rat [8]
and in the regulation of intraocular pressure in the rabbit [9].
Figure 1. Chemical structures of melatonin, agomelatine and ramelteon.
NHCOCH3
NHCO2C2H5
NHCOCH3
O
O
O
N
Agomelatine
Ramelteon
Melatonine
In fact and in order to clarify MT1, MT2 and MT3 biological functions, over the last years several
ligands were synthesized [10–19]. Only ramelteon (Rozerem®) [20] and agomelatine (Valdoxan®) [21],
two MT1 and MT2 receptor agonists, are respectively marketed for the treatment of insomnia and major
depressive disorders. Agomelatine is the first antidepressant which does not block the reuptake of
monoamines. Therefore it might represent the prototype of a new class of antidepressant drugs. The
development of new derivatives is of importance in order to increase efficacy and reduce side effects.
Agomelatine, which is also a 5-HT2C selective antagonist was revealed to be also potent in resynchronization
of circadian rhythms [22,23].
The importance of melatonin as a promising therapeutic target has led to the investigation of the
pharmacophoric requirements for its receptors’ binding and activation in order to develop selective
ligands. Early SAR studies showed that both methoxy group and the N-acetylamino side chain of
melatonin are crucial for high receptor affinity and that the relative spatial distance between these groups
is also an important factor [24]. In addition, 3D-QSAR analysis of melatoninergic ligands revealed that
MT1 and MT2 binding affinity could be enhanced by replacement and/or conformationally restriction of
the amide substituent [25]. This approach could help probing the existing pharmacophore for potent MT1
and MT2 selective ligands, and open new therapeutic perspectives by targeting a specific receptor.
In our continuing efforts to develop new melatonin ligands using the agomelatine as a lead, we
previousely reported the design and synthesis of melatoninergic MT1 [26,27], MT2 [28–31] and
MT3-selective ligands [32–34]. We also were the pioneers in preparing non-selective MT1 and MT2
ligands with 5-HT2C activity [17]. In this paper we describe the synthesis and pharmacological
evaluation of a novel small series of naphtalenic constrained compounds issued from the incorporation
of the amide side chain into heterocycles.

Molecules 2013, 18
156
2. Results and Discussion
2.1. Chemistry
The target compounds 3 and 4 were prepared from 2-(7-methoxynaphth-1-yl)acetonitrile [35].
Compound 3 was obtained via a two steps reaction sequence: (1) treatment with hydroxylamine
hydrochloride and sodium methoxide in DMSO to afford the amidoxime 1 in accordance with a
literature procedure [36]; (2) cyclization with thionyl chloride according to Scheme 1. Compound 2,
which was obtained from amidoxime 1 by reaction with ethyl chloroformate, was cyclized by treatment
with potassium carbonate to provide oxadiazolone 4 [37].
Scheme 1. Synthesis of compounds 3 and 4.
OH
N
NOCO2C2H5
NH2
CN
NH2
O
O
O
i
ii
2
1
O
N
O
S
iv
iii
N
O
O
N
H
N
H
O
O
3
4
Reagents and conditions: (i) NH2OH.HCl, NaOMe, MeOH/DMSO, 80 °C; (ii) ClCO2Et, NEt3, THF,
reflux; (iii) SOCl2, pyridine, CH2Cl2, 0 °C; (iv) K2CO3, DMF, 60 °C.
Scheme 2 illustrates the synthetic route to naphthalenic compounds 5–9. Treatment of
2-(7-methoxynaphth-1-yl)acetonitrile with sodium azide in the presence of tributyltin chloride in DMF
gave the desired tetrazole 5 [38]. N-acetylated derivatives 6a,b were derived from
2-(7-methoxynaphth-1-yl)acetonitrile by reduction of the nitrile group and reaction with the appropriate
acyl chloride. Carbamate 6a was then cyclized by heating in an alkaline solution (NaOH) to afford the
desired oxazolidinone 7a [39]. Compounds 6b and 7b were synthesized as previously described by us [40].
The agomelatine 8 was converted to cyclic 9a and 9b by heating in a large excess of DMSO [41].
Finally, synthesis of compounds 12–15 was carried out as illustrated in Scheme 3.
2-(7-methoxynaphth-1-yl)acetaldehyde (11) was obtained from (7-methoxynaphth-1-yl)acetic acid [21]
via esterification followed by reduction and Dess Martin oxidation [42]. Compound 11 was then
converted to the desired imidazolidine-dione 12 by treatment with potassium cyanide and ammonium
carbonate. Compounds 13–15 were prepared under the same conditions by condensation of 11 with the
appropriate heterocyclic amine, followed by reduction of the imine generated in situ by use of sodium
cyanoborohydride in the presence of zinc iodide.

Molecules 2013, 18
157
Scheme 2. Synthesis of compounds 7a,b and 9a,b.
N
N
O
N
N
H
N
X
O
O
5
7a X = O
7b X = CH2
iii
i
O
Cl
CN
N
H
X
O
O
ii
6a X = O
6b X = CH2
iv
O
N
O
O
N
H
N
O
O
O
v
+
9a
8
9b
Reagents and conditions: (i) Bu3SnCl, NaN3, DMF, 130 °C; (ii) a) H2, Raney nickel, EtOH, NH3
(gas), 50 bars, 60 °C; b) ClCO2(CH2)2Cl or ClCO(CH2)3Cl, NEt3, THF, rt; (iii) 20% NaOH, THF,
reflux; (iv) H2, Raney nickel, (CH3CO)2O, 50 bars, 60 °C, 4 h; (v) DMSO, reflux.
Scheme 3. Synthesis of compounds 12–15.
O
OH
OH
O
O
i
10
O
NH
ii
O
N
HN
O
N
H
H
O
O
O
O
.HCl
vi
iii
15
11
12
v
iv
N
N
S
S
N
N
H
H
O
O
.HCl
13
14
Reagents and conditions: (i) SOCl2, MeOH, 0 °C then LiAlH4, Et2O, rt; (ii) Dess-Martin Periodinane,
CH2Cl2, rt; (iii) KCN, (NH4)2CO3, EtOH/H2O, reflux; (iv) 2-amino-1,3-thiazole, NaBH3CN/ZnI2,
MeOH, rt then HCl(gas)/Et2O; (v) 2-amino-5-methyl-1,3-thiazole, NaBH3CN/ZnI2, MeOH, rt;
(vi) 3-amino-5-methyl-1,2-isoxazole, NaBH3CN/ZnI2, MeOH, rt then HCl(gas)/Et2O.

Molecules 2013, 18
158
2.2. Pharmacology
2.2.1. Reagents and Chemicals
2-[125I]Iodomelatonin (2200 Ci/mmol) was purchased from NEN (Boston, MA, USA). Other drugs
and chemicals were purchased from Sigma–Aldrich (Saint Quentin, France).
2.2.2. Assays for MT1 and MT2 Receptor Subtypes
2-[125I]Iodomelatonin binding assay conditions were essentially as previously described [43]. Briefly,
binding was initiated by addition of membrane preparations from transfected CHO cells stably
expressing the human melatonin MT1 or MT2 diluted in binding buffer (50 mM Tris–HCl buffer, pH 7.4,
containing 5 mM MgCl2) to 2-[125I]iodomelatonin (20 pM for MT1 and MT2 receptors expressed in CHO
cells) and the tested drug. Non-specific binding was defined in the presence of 1 µM melatonin. After
120 min incubation at 37 °C, reaction was stopped by rapid filtration through GF/B filters presoaked in
0.5% (v/v) polyethylenimine. Filters were washed three times with 1 mL of ice-cold 50 mM Tris–HCl
buffer, pH 7.4. Data from the dose–response curves (seven concentrations in duplicate) were analysed
using the program PRISM (Graph Pad Software Inc., San Diego, CA, USA) to yield IC50 (inhibitory
concentration 50). Results are expressed as pKi (pKi = −Log10 (Ki)) with Ki = IC50/1 + ([L]/KD),
where [L] is the concentration of radioligand used in the assay and KD, the dissociation constant of the
radioligand characterizing the membrane preparation.
2.3. Discussion
Conformationally restricted ligands for melatonin receptors were synthesized and their binding
affinities at human MT1 and MT2 receptors were determined. The data summarized in Table 1
emphasized the lack of good affinities for the MT1 and MT2 receptors of the prepared compounds. In
fact, in comparison with agomelatine the lock of the ethylamido side chain conformation by its
incorporation in rigid structures led to the decrease of the binding affinities at both receptors. This
decrease of the melatoninergic binding affinities is more noticeable for the MT1 than the MT2 leading to
the appearance of a weak MT2-selectivity. Only compounds 7a and 7b showed an interesting
pharmacological profile by conserving a good binding affinity (10−8 M) at MT2 receptors subtypes.
Table 1. MT1 and MT2 binding affinities of naphtalenic cyclized compounds.
Ki (nM)
MT1
Ki (nM)
MT2
S
Compound
(MT1/MT2)
Melatonin
0.2 ± 0.02
0.1 ± 0.01
>1,000
0.3 ± 0.03
0.12 ± 0.02
1300
0.17
0.83
>0.77
3
Agomelatine
3
4
80.0 ± 16.0
380 ± 114
113 ± 18
68.5 ± 18.2
25.2 ± 10.7
190 ± 84
6.0 ± 0.2
2.1 ± 0.01
5
2
7a
7b
19
33

Molecules 2013, 18
159
Table 1. Cont.
Ki (nM)
MT1
Ki (nM)
MT2
S
Compound
(MT1/MT2)
9a
9b
12
13
14
15
2500 ± 57
3000 ± 27
2170 ± 63
33.9 ± 8.1
389 ± 121
48.4 ± 11.2
469 ± 44
800 ± 59
141 ± 31
12.5 ± 0.4
354 ± 32
20.3 ± 3.9
5.4
3.75
15.4
3
1
2
3. Experimental
3.1. General
All common reagents and solvents were obtained from commercial sources (Sigma-Aldrich Alfa
Aesar or Acros Organics) and used without further purification. Compounds were purified on a glass
column using Merck Silica Gel 60 (230–400 mesh). Their purity and mass spectra were determined on a
Surveyor MSQ Thermoelectron spectrometer (+cAPCI corona sid = 30.00, det = 1400.00 Full ms
[100.00–1000.00]). Melting points were determined with a büchi 510 capillary apparatus and are
1
uncorrected. H-NMR spectra were recorded on a Bruker AC300P spectrometer using (Me)4Si as
internal standard and with DMSO-d6 or CDCl3 as solvents; The chemical shifts are reported in ppm
(parts per million) δ and constant (J) values are given in Hertz (Hz). Signal multiplicities are represented
by: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), dt (doublet of triplet), q (quartet) and m
(multiplet). Infrared spectra were obtained on a Perkin-Elmer FT-IR S1000 in KBr pellets. Elemental
analyses for final compounds were performed by CNRS Laboratory (Vernaison, France).
2-(7-Methoxynaphth-1-yl)acetamidoxime (1). A mixture of 2-(7-methoxynaphth-1-yl)acetonitrile (5 g,
25.3 mmol) and hydroxylamine hydrochloride (3.52 g, 50.6 mmol) in DMSO (20 mL) was treated with
25% NaOMe solution in methanol (11.5 mL, 50.6 mmol) and heated at 80 °C for 5 h. After cooling, the
solvent was evaporated under reduced pressure. The crude was taken with water, the white solid
obtained was washed with water and recrystallized from toluene to afford 3.8 g (65% yield) of 1 as a
white solid, mp: 151–153 °C. 1H-NMR (300 MHz, DMSO-d6) δ: 3.71 (s, 2H), 3.88 (s, 3H), 5.38 (s, 2H),
7.17 (dd, J = 8.9, 2.2 Hz, 1H), 7.27 (t, J = 7.6 Hz, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H),
7.60 (d, J = 2.2 Hz, 1H), 7.82 (d, J = 8.9 Hz, 1H), 8.96 (s, 1H). IR (cm−1) 1660 (C=N), 3360, 3460 (NH),
3100–3400 (OH). MS (EI): m/z = 231 [M+H]+.
N-[(Ethoxycarbonyl)oxy]-2-(7-methoxynaphth-1-yl)acetamidoxime (2). Ethyl chloroformate (0.84 mL,
8.8 mmol) was added dropwise to a suspension of 1 (2 g, 8.7 mmol) and triethylamine (2.4 mL, 17.4 mmol)
in 25 mL of THF. Stirring was maintained for 3 h at ambient temperature. The reaction mixture was then
filtered and the filtrate was evaporated under reduced pressure. The crude was purified by column
chromatography (SiO2, acetone/toluene/cyclohexane: 2/3/5) to give 2.3 g (88% yield) of 2 as a pink
solid, mp: 104–106 °C. 1H-NMR (300 MHz, DMSO-d6 at 50 °C) δ: 1.22 (t, J = 7.1 Hz, 3H), 3.82 (s, 2H),

Molecules 2013, 18
160
3.91 (s, 3H), 4.14 (q, J = 7.1 Hz, 2H), 6.13 (s, 2H), 7.16 (dd, J = 9.1, 2.5 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H),
7.51 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 7.6 Hz, 1H), 7.64 (d, J = 2.5 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H). IR
(cm−1) 1680 (C=N), 1730 (C=O), 3340, 3460 (NH). MS (EI): m/z = 303 [M+H]+.
4-[(7-Methoxynaphth-1-yl)methyl]-3H-1,2,3,5-oxathiadiazole 2-oxide (3). Thionyl chloride (0.5 mL,
6.7 mmol) in methylene chloride (2 mL) was added dropwise to a mixture of 1 (1.4 g, 6.1 mmol) in
methylene chloride (20 mL) and pyridine (1 mL, 12.2 mmol) at 0 °C. After stirring for 3 h at room
temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic
layer was dried over MgSO4, filtered and concentrated under reduced pressure. The residue was
recrystallized from cyclohexane/toluene and ethyl ether/petroleum ether to afford 791 mg (47% yield) of
4 as a white solid, mp: 121–123 °C (decomp.). 1H-NMR (300 MHz, DMSO-d6) δ: 3.88 (s, 3H), 4.36 (d,
J = 16.3 Hz, 1H), 4.42 (d, J = 16.3 Hz, 1H), 7.21 (dd, J = 8.9, 2.3 Hz, 1H), 7.29–7.49 (m, 3H), 7.78–7.94
(m, 2H), 11.40 (s, 1H). IR (cm−1) 1620 (C=N), 3300 (NH). MS (EI): m/z = 277 [M+H]+. Anal. Calcd for
C13H12N2O3S: C, 56.51%; H, 4.38%; N, 10.14%. Found: C, 56.55%; H, 4.43%, N, 10.15%.
3-[(7-Methoxynaphth-1-yl)methyl]-1,2,4-oxadiazole-5(4H)-one (4). Potassium carbonate (1.1 g, 8 mmol)
was added to a solution of 2 (1.2 g, 4 mmol) in DMF (10 mL). After 5 h of stirring at 60 °C, the reaction
mixture was poured into water and extracted twice with ethyl acetate. The aqueous phase was acidified
with a 3 M HCl solution and extracted with ethyl acetate. The combined organic phases were washed
with water and brine, dried (MgSO4), filtered, and concentrated under reduce pressure. The residue was
recrystallized from toluene to give 712 mg of 3 (yield 70%) as a white solid, mp: 185–187 °C (decomp.).
1H-NMR (300 MHz, DMSO-d6) δ:3.89 (s, 3H), 4.33 (m, 2H), 7.23 (dd, J = 8.6, 2.5 Hz, 1H), 7.34 (t,
J = 7.40 Hz, 1H), 7.39 (d, J = 2.50 Hz, 1H), 7.44 (d, J = 7.40 Hz, 1H), 7.83 (d, J = 7.40 Hz, 1H), 7.89 (d,
J = 8.6 Hz, 1H), 11.40 (s, 1H). IR (cm−1) 1725 (C=N), 3440 (NH). MS (EI): m/z = 257 [M+H]+. Anal.
Calcd for C14H12N2O3: C, 65.61%; H, 4.72%; N, 10.93%. Found: C, 65.64%; H, 4.76%; N, 10.90%.
5-(7-Methoxynaphth-1-yl methyl)-1H-tetrazole (5). A mixture of 2-(7-methoxynapht-1-yl)acetonitrile
(2 g, 1.01 mmol), sodium azide (2.62 g, 40.4 mmol) and tributyltin chloride (10.9 mL, 40.4 mmol) in dry
DMF (20 mL) was heated to reflux and monitored by TLC until the reaction was complete (~7 h). After
being cooled to room temperature, 1 M HCl (50 mL) was added to precipitate the crude product. The
white solid product was collected, washed with water and ether, and dried with phosphorous pentoxide
under vacuum and recrystallized from cyclohexane affording 1.21 g (50% yield) of tetrazole 5 as a beige
solid, mp: 177–179 °C (decomposition). 1H-NMR (300 MHz, DMSO-d6 + D2O) δ: 3.88 (s, 3H), 4.74 (s,
2H), 7.22 (dd, J = 9.1, J = 2.3 Hz, 1H), 7.31–7.47 (m, 3H), 7.83 (d, J = 7.6 Hz, 1H), 7.90 (d, J = 9.1 Hz,
1H), 7.81 (d, J = 9.1 Hz, 1H). MS (EI): m/z = 241 [M+H]+.
N-(2-Chloroethyl)oxycarbonyl)-2-(7-methoxynaphth-1-yl)ethylamine (6a). 2-Chloroethyl chloroformate
(0.87 mL, 8.41 mmol) and triethylamine (1.2 mL, 8.41 mmol) were added to a solution of
2-(7-methoxynaphth-1-yl)ethylamine hydrochloride (2 g, 8.41 mmol) in THF (30 mL). The reaction
mixture was stirred at room temperature for 36 h. After filtration, the filtrate was concentrated under
vacuum and purified by column chromatography (SiO2) using cyclohexane/ethyl acetate; 8/2 as eluant to
gave 1.7 g (65% yield) of carbamate 6a as a white solid, mp: 73–75 °C. 1H-NMR (300 MHz, DMSO-d6)
δ: 3.04–3.34 (m, 4H), 3.80 (t, J = 5.2 Hz, 2H), 3.94 (s, 3H), 4.24 (t, J = 5.2 Hz, 2H), 7.18 (dd, J = 9.1,

Molecules 2013, 18
161
2.1 Hz, 1H), 7.22–7.42 (m, 2H), 7.53 (d, J = 2.1 Hz, 1H), 7.60 (t, J = 5.4 Hz, 1H), 7.72 (d, J = 7.9 Hz,
1H), 7.84 (d, J = 9.1 Hz, 1H). MS (EI): m/z = [M+H]+.
N-[(2-(7-methoxynaphth-1-yl)]-1,3-oxazolidin-2-one (7a). A mixture of carbamate 6a (1.2 g, 3.9 mmol)
and 20% NaOH (3 mL, 15 mmol) in THF (20 mL) were refluxed for 39 h. The residue was evaporated to
dryness, water was added, and the mixture was stirred and extracted with ethyl acetate. The combined
organic phases were washed with water (50 mL), dried (MgSO4), filtered and concentrated under
vacuum. The residue was purified by column chromatography (SiO2, cyclohexane/ethyl acetate, 6/4) to
afford 868 mg (82% yield) of 7a as a white solid, mp 78–80 °C. 1H-NMR (300 MHz, DMSO-d6) δ: 3.24
(m, 2H), 3.47 (m, 2H), 3.56 (t, J = 8.28 Hz, 2H), 3.92 (s, 3H), 4.22 (t, J = 8.37 Hz, 2H), 7.17 (dd,
J = 8.97, 2.40 Hz, 1H), 7.30 (m, 1H), 7.36 (d, J = 6.48 Hz, 1H), 7.46 (d, J = 2.41 Hz, 1H); 7.72 (d,
J = 8.00 Hz, 1H), 7.83 (d, J = 8.97 Hz, 1H). MS (EI): m/z = 272 [M+H]+.
3.2. General Protocol for the Preparation of Compounds 9a and 9b
A solution of agomelatine (4 g, 16.4 mmol) in DMSO (100 mL) was refluxed for 15 h. The reaction
mixture was poured into ice and extracted twice with ether, organic phase was washed with water and
brine and then concentrated under reduced pression. The crude was purified by column chromatography
(SiO2) using ether as eluant.
1-(10-Methoxy-1,2,3,4-tetrahydro-naphto[1,8-cd]azepin-2-yl)ethanone (9a). Recrystallized from
1
isopropyl ether to furnish 1.59 g (38% yield) as a white solid, mp: 107–108 °C. H-NMR (300 MHz,
75 °C, DMSO-d6) δ: 1.88 (s, 3H), 3.44 (t, J = 6.3 Hz, 2H), 3.81 and 3.87 (t, t, 2H), 3.93 and 3.97 (s, s,
3H), 5.11 and 5.20 (s, s, 2H), 7.21–7.30 (m, 2H), 7.34 and 7.41 (d, d, J = 9.2 Hz, 1H), 7.69–7.73 (m, 1H),
7.77 and 7.83 (d, d, J = 9.2 Hz, 1H). IR (cm−1) 1625 (C=O). MS (EI) m/z = 256 [M+H]+. Anal. Calcd for
C16H17NO2: C, 75.27%; H, 6.71%; N, 5.49%. Found: C, 75.25%; H, 6.72%; N, 5.48%.
1-(9-Methoxy-1,2,3,4-tetrahydro-benzo[f]isoquinolein-3-yl)ethanone (9b). Recrystallized from
isopropyl ether, 9b was obtained with 2% yield as a white solid, mp: 141–143 °C. 1H-NMR (300 MHz,
60 °C, DMSO-d6) δ: 2.14 (s, 3H), 3.10 (m, 2H), 3.84 (t, J = 6.0 Hz, 2H), 3.92 (s, 3H), 4.75 (s, 2H), 7.16
(m, J = 8.3 Hz, 1H), 7.17 (dd, J = 8.8 Hz, 1H), 7.27 (m, 1H), 7.69 (d, J = 8.3 Hz, 1H), 7.81 (d, J = 8.8 Hz,
1H). IR (cm−1) 1620 (CO). MS (EI): m/z = 256 [M+H]+. Anal. Calcd for C16H17NO2: C, 75.27%; H,
6.71%; N, 5.49%. Found: C, 75.29%; H, 6.72%; N, 5.45%.
2-(7-Methoxynaphth-1-yl)ethanol (10). Thionyl chloride (27 mL, 370 mmol) was added dropwise to a
solution of (7-methoxynaphth-1-yl) acetic acid (20 g, 92.5 mmol) in methanol (350 mL) at 0 °C. After
stirring for 5 h, the reaction mixture was evaporated under reduced pressure. The residue was dissolved
in ethyl acetate and washed with 10% aqueous potassium carbonate solution and water. The organic
layer was dried over MgSO4, filtered and concentrated under reduced pressure affording the
intermediate ester. The residue was dissolved in ether (100 mL) and added dropwise to a suspension of
lithium aluminium hydride (12.4 g, 327 mmol) in ether (200 mL) at 0 °C. The stirring was maintained at
room temperature for 4 h. Water (50 mL) and 20% NaOH aqueous solution (12 mL) were added and the
mixture was stirred and filtered. After evaporation under reduced pressure, the residue was recrystallized

Molecules 2013, 18
162
from cyclohexane to furnish 13.7 g (73% yield) of alcohol 10 as a white solid, mp: 79–81 °C. 1H-NMR
(300 MHz, CDCl3+D2O) δ: 3.30 (t, J = 6.69 Hz, 2H), 3.94 (s, 3H), 3.99 (t, J = 6.75, 2H), 7.17 (dd,
J = 9.2, 2.3 Hz, 1H), 7.24–7.38 (m, 3H), 7.68 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 9.2 Hz, 1H). IR (cm−1)
3000–3330 (OH). MS (EI): m/z = 203 [M+H]+.
2-(7-Methoxynaphth-1-yl)acetaldehyde (11). To a stirred solution of alcohol 10 (6 g, 29.6 mmol) in
anhydrous CH2Cl2 (300 mL) under argon atmosphere was added Dess-Martin periodinane (25 g,
59.2 mmol) and stirred at room temperature for 5 h. The reaction mixture was quenched by adding
saturated Na2S2O4 (60 mL) and saturated NaHCO3 (8 mL). The heterogeneous mixture was extracted
with CH2Cl2 and the organic layer was washed with saturated NaHCO3 and water. The combined
organic layers were dried over MgSO4 and the solvent removed under reduced pressure. The residue was
purified by column chromatography (SiO2, CH2Cl2) to give 5.2 g (87% yield) of 11 as a yellow oil.
1H-NMR (300 MHz, CDCl3 + D2O) δ: 3.91 (s, 3H), 4.03 (d, J = 2.3 Hz, 2H), 7.08–7.87 (m, 6H), 9.73 (t,
J = 2.3 Hz, 1H). IR (cm−1) 1700 (C=O). MS (EI): m/z = 201 [M+H]+.
5-[(7-Methoxynaphth-1-yl)methyl]-imidazolidin-2,4-diones (12). Ammonium carbonate (1.67 g, 17.4 mmol)
and potassium cyanide (341 mg, 5.24 mmol) were added to a stirred solution of aldehyde 14 (700 mg,
3.49 mmol) in 20 mL (16 mL/4 mL) of ethanol/water, the mixture was refluxed overnight. After cooling,
the reaction mixture was poured into cold water. The resulting precipitate was filtrated, washed with
water and recrystallized from isopropyl ether affording 400 mg (42% yield) of 15 as a white solid, mp:
1
236–238 °C (decomp.). H-NMR (300 MHz, DMSO-d6) δ: 3.26 (m, 2H), 3.92 (s, 3H), 4.44 (m, 1H),
7.06–7.97 (m, 7H), 10.56 (s, 1H). IR (cm−1) 1680, 1750 (C=O), 3270 (NH). MS (EI): m/z = 271 [M+H]+.
Anal. Calcd for C15H14N2O3: C, 66.65%; H, 5.22%; N, 10.36%. Found: C, 65.68%; H, 5.25%, N, 10.38%.
3.3. General Protocol for the Preparation of Compounds 13–15
To a mixture of compound 11 (0.5 g, 2.49 mmol) and the appropriate heterocyclic amine (10 mmol)
in methanol (20 mL) and 0.2 mL of DMF, were added a solution of sodium cyanoborohydride (172 mg,
2.73 mmol) and zinc iodide (437 mg, 1.36 mmol) in methanol (5 mL). The reaction was stirred at room
temperature for 5 h and concentrated under reduced pressure to dryness, hydrolyzed and extracted with
ethyl acetate. The organic layer was dried (MgSO4), filtered, and concentrated under reduced pressure.
2-[2-(7-Methoxynaphth-1-yl)]-ethylamino]-1,3-thiazole hydrochloride (13). The crude was purified by
column chromatography (SiO2) using cyclohexane/ethyl acetate; 7/3 as eluant, treatment with gaseous
HCl in ether provided 280 mg (35% yield) of hydrochloride salt 13 as a white solid, mp: 156–158 °C.
1H-NMR (300 MHz, DMSO-d6) δ: 3.38 (t, J = 7.1 Hz, 2H), 3.81 (m, 2H), 3.93 (s, 3H), 6.92 (d, J = 4.3 Hz,
1H), 7.19 (dd, J = 9.0, 2.4 Hz, 1H), 7.25–7.49 (m, 4H), 7.75 (m, 2H), 10.22 (s, 1H). IR (cm−1)
2500–3160 (N+H). MS (EI): m/z = 285 [M+H]+. Anal. Calcd for C16H17ClN2OS: C, 59.90%; H, 5.34%;
N, 8.73%. Found: C, 59.94%; H, 5.32%, N, 8.75%.
2-[2-(7-Methoxynaphth-1-yl)ethylamino]-5-methyl-1,3-thiazole (14). Recrystallized from cyclohexane
to furnish 364 mg (46% yield) of 14 as a white solid, mp: 150–152 °C (decomp.). 1H-NMR (300 MHz,
DMSO-d6 + D2O) δ: 2.22 (s, 3H), 3.28 (t, J = 7.5 Hz, 2H), 3.47 (m, 2H), 3.95 (s, 3H), 6.71 (s, 1H),

Molecules 2013, 18
163
7.11–7.89 (m, 6H). IR (cm−1) 3170 (NH). MS (EI): m/z = 299 [M+H]+. Anal. Calcd for C17H18N2OS: C,
68.43%; H, 6.08%; N, 9.39%. Found: C, 68.39%; H, 6.13%, N, 9.36%.
3-[2-(7-Methoxynaphth-1-yl)ethylamino]-5-methyl-1,2-isoxazole hydrochloride (15). Recrystallized
from cyclohexane to afford 333 mg (42% yield) of 15 as a white solid, mp 144–146 °C (decomp.).
1H-NMR (300 MHz, DMSO-d6 + D2O) δ: 2.24 (s, 3H), 3.18–3.39 (m, 4H), 3.93 (s, 3H), 5.67 (s, 1H),
7.15 (dd, J = 9.1, 2.1 Hz, 1H), 7.21–7.39 (m, 2H), 7.65 (d, J = 2.1 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.81
(d, J = 9.1 Hz, 1H). IR (cm−1) 2200–3000 (N+H). MS (EI): m/z = 283 [M+H]+. Anal. Calcd for C17H19Cl
N2O2: C, 64.05%; H, 6.01%; N, 8.79%. Found: C, 64.07%; H, 6.04%, N, 8.76%.
4. Conclusions
In the search for pharmacological tools for the elucidation of MT1 and MT2 biological functions, we
synthesized and pharmacologically evaluated a new series of constrained naphthalenic compounds.
Indeed, replacement of the N-acetyl side chain of agomelatine by oxathiadiazole-2-oxide,
oxadiazole-5(4H)-one,
oxazolidinone,
2-oxopyrrolidine,
imidazolidin-2,4-dione,
thiazole,
5-methyl-1,3-thiazole, or 5-methyl-1,2-isoxazole hydrochloride resulted in a decrease of the
melatoninergic binding affinities particularly towards the MT1 receptors leading to the appearance of a
weak MT2-selectivity. Compound 7b conserves good affinity for both melatonin receptors subtypes and
exhibited a selectivity of about 33-fold for the MT2 receptor subtype.
Acknowledgments
This research was supported by the Laboratoires Servier. We are grateful to the Région Nord-Pas de
Calais (France), the Ministère de la Jeunesse, de l’Education Nationale et de la Recherche (MJENR,
France) and the Fonds Européens de Développement Régional (FEDER) for the funding for the
300 MHz NMR facilities.
References
1. Lerner, A.B.; Case, J.D.; Heinzelman, R.V. Structure of melatonin. J. Am. Chem. Soc. 1959, 81,
6084–6085.
2. Guerrero, J.M.; Reiter, R.J. Melatonin-Immune System Relationships. Curr. Top. Med. Chem.
2002, 2, 167–169.
3. Dubocovich, M.L.; Mansana, M.I.; Benloucif, S. Molecular pharmacology and function of
melatonin receptor subtype. Adv. Exp. Med. Biol. 1999, 460, 181–190.
4. Malpaux, B.; Migaud, M.; Tricoire, H.; Chemineau, P. Biology of Mammalian Photoperiodism and
the Critical Role of the Pineal Gland and Melatonin. J. Biol. Rhythms. 2001, 16, 336–347.
5. Reiter, R.J. The melatonin rhythm: Both a clock and a calendar. Experientia 1993, 49, 654–664.
6. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchere, J.L.;
Delagrange, P.; Canet, E.; Boutin, J.A. MT1 melatonin receptors mediate somatic, behavioral, and
reproductive neuroendocrine responses to photoperiod and melatonin in Siberian hamsters. J. Biol.
Chem. 2000, 275, 31311–31317.

Molecules 2013, 18
164
7. Vella, F.; Ferry, G.; Delagrange, P.; Boutin, J.A.; NRH: Quinone reductase 2: An enzyme of
surprises and mysteries. Biochem. Pharmacol. 2005, 71, 1–12.
8. Lotufo, C.M.C.; Lopes, C.; Dubocovich, M.L.; Farsky, S.H.P.; Markus, R.P. Melatonin and
N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur. J. Pharmacol.
2001, 430, 351–357.
9. Pintor, J.; Martin, L.; Pelaez, T.; Hoyle, C.H.V.; Peral, A. Involvement of melatonin MT3 receptors
in the regulation of intraocular pressure in rabbits. Eur. J. Pharmacol. 2001, 416, 251–254.
10. Zlotos, D.P. Recent Advances in Melatonin Receptor Ligands. Arch. Pharm. Chem. Life Sci. 2005,
338, 229–247.
11. Garratt, P.J.; Tsotinis, A. Synthesis of compounds as melatonin agonists and antagonists. Mini-Rev.
Med. Chem. 2007, 7, 1075–1088.
12. Carocci, A.; Catalano, A.; Lovece, A.; Lentini, G.; Duranti, A.; Lucini, V.; Pannacci, M.; Scaglione,
F.; Franchini, C. Design, synthesis, and pharmacological effects of structurally simple ligands for
MT1 and MT2 melatonin receptors. Bioorg. Med. Chem. 2010, 18, 6496–6511.
13. Tsotinis, A.; Afroudakis, P.A.; Davidson, K.; Prashar, A.; Sugden, D. Design, Synthesis, and
Melatoninergic Activity of New Azido- and Isothiocyanato-Substituted Indoles. J. Med. Chem.
2007, 50, 6436–6440.
14. Nonno, R.; Pannacci, M.; Lucini, V.; Angeloni, D.; Fraschini, F.; Stankov, B.M. Ligand efficacy
and potency at recombinant human MT2 melatonin receptors: Evidence for agonist activity of some
MT1-antagonists. Br. J. Pharmacol. 1999, 127, 1288–1294.
15. Fisher, S.P.; Sugden, D. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor
agonist in the rat. Neurosci. Lett. 2009, 457, 93–96.
16. Koike, T.; Hoashi, Y.; Takai, T.; Nakayama, M.; Yukuhiro, N.; Ishikawa, T.; Hirai, K.; Uchikawa, O.
1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: Design, synthesis and pharmacological
characterization of a novel class of highly potent MT2-selective agonists. J. Med. Chem. 2011, 54,
3436–3444.
17. Ettaoussi, M.; Sabaouni, A.; Rami, M.; Boutin, J.A.; Delagrange, P.; Renard, P.; Spedding, M.;
Caignard, D.H.; Berthelot, P.; Yous, S. Design, synthesis and pharmacological evaluation of new
series of naphthalenicanalogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual
ligands (I). Eur. J. Med. Chem. 2012, 49, 310–323.
18. Markl, C.; Attia, M.I.; Julius, J.; Sethi, S.; Witt-Enderby, P.A.; Zlotos, D.P. Synthesis and
pharmacological evaluation of 1,2,3,4-tetrahydropyrazino [1,2-a]indole and 2-[(phenylmethyl-
amino)methyl]-1H-indole analogues as novel melatoninergic ligands. Bioorg. Med. Chem. 2009,
17, 4583–4594.
19. Attia, M.I.; Witt-Enderby, P.A.; Julius, J. Synthesis and pharmacological evaluation of pentacyclic
6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands. Bioorg.
Med. Chem. 2008, 16, 7654–7661.
20. Simpson, D.; Curran, M.P. Ramelteon: A review of its use in Insomnia. Drugs 2008, 68,
1901–1919.
21. Montgomery, S.A. Major depressive disorders: Clinical efficacy and tolerability of agomelatine,
a new melatonergicagonist. Eur. Neuropsychopharmacol. 2006, 16, S633–S638.

Molecules 2013, 18
165
22. Dagyte, G.; Trentani, A.; Postema, F.; Luiten, P.G.; Den Boer, J.A.; Gabriel, C.; Mocaër, E.;
Meerlo, P.; Van der Zee, E. The novel antidepressant agomelatine normalizes hippocampal
neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neurosci. Ther.
2010, 16, 195–207.
23. Dagyte, G.; Luiten, P.G.; De Jager, T.; Gabriel, C.; Mocaër, E.; Den Boer, J.A.; Van der Zee, E.
Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I
expression in the rat brain. J. Neurosci. Res. 2011, 89, 1646–1657.
24. Mathé-Allainmat, M.; Andrieux, J.; Langlois, M. Recent developments in melatonin receptor
ligands. Expert Opin. Ther. Pat. 1997, 7, 1447–1458.
25. Marot, C.; Chavatte, P.; Morin-Allory, L.; Guillaumet, G.; Viaud-Massuard, M.C.; Renard, P.;
Lesieur, D.; Michel, A. Pharmacophoric Search and 3D-QSAR Comparative Molecular Field
Analysis Studies on Agonists of Melatonin Sheep Receptors. J. Med. Chem. 1998, 41, 4453–4465.
26. Mésangeau, C.; Pérès, B.; Descamps-François, C.; Chavatte, P.; Audinot, V.; Coumailleau, S.;
Boutin J.A.; Delagrange, P.; Bennejean, C.; Renard P.; et al. Design, synthesis and
pharmacologicalevaluation of novelnaphthalenicderivatives as selective MT1 melatoninergic
ligands. Bioorg. Med. Chem. 2010, 18, 3426–3436.
27. Descamps-François, C.; Yous, S.; Chavatte, P.; Audinot, V.; Bonnaud, A.; Boutin, J.A.;
Delagrange, P.; Bennejean, C.; Renard, P.; Lesieur, D. Design and synthesis of naphthalenic dimers
as selective MT1 melatoninergic ligands. J. Med. Chem. 2003, 46, 1127–1129.
28. Mésangeau, C.; Fraise, M.; Delagrange, P.; Caignard, D.H.; Boutin, J.A.; Berthelot, P.; Yous, S.
Preparation and pharmacological evaluation of a novel series of 2-(phenylthio) benzo[b]thiophenes
as selective MT2 receptor ligands. Eur. J. Med. Chem. 2011, 46, 1835–1840.
29. Durieux, S.; Chanu, A.; Bochu, C.; Audinot, V.; Coumailleau, S.; Boutin, J.A.; Delagrange, P.;
Caignard, D.H.; Bennejean, C.; Renard, P.; et al. Design and synthesis of
3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.
Bioorg. Med. Chem. 2009, 17, 2963–2974.
30. Poissonnier-Durieux, S.; Ettaoussi, M.; Pérès, B.; Boutin, J.A.; Audinot, V.; Bennejean, C.;
Delagrange, P.; Caignard, D.H.; Renard, P.; Berthelot, P.; et al. Synthesis of 3-phenylnaphthalenic
derivatives as new selective MT2 melatoninergic ligands. Bioorg. Med. Chem. 2008, 16,
8339–8348.
31. Yous, S.; Durieux-Poissonnier, S.; Lipka-Belloli, E.; Guelzim, H.; Bochu, C.; Audinot, V.; Boutin,
J.A.; Delagrange, P.; Bennejean, C.; Renard, P.; et al. Design and synthesis of 3-phenyl
tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Bioorg. Med.
Chem. 2003, 11, 753–759.
32. Leclerc, V.; Ettaoussi, M.; Rami, M.; Farce, A.; Boutin, J.A.; Delagrange, P.; Caignard, D.H.;
Renard, P.; Berthelot, P.; Yous, S. Design and synthesis of naphthalenic derivatives as new ligands
at the melatoninbinding site MT3. Eur. J. Med. Chem. 2011, 46, 1622–1629.
33. Ettaoussi, M.; Péres, B.; Klupsch, F.; Delagrange, P.; Boutin, J.A.; Renard, P.; Caignard, D.H.;
Chavatte, P.; Berthelot, P.; Lesieur, D.; et al. Design and synthesis of benzofuranic derivatives as
new ligandsat the melatonin-binding site MT3. Bioorg. Med. Chem. 2008, 16, 4954–4562.

Molecules 2013, 18
166
34. Leclerc, V.; Yous, S.; Delagrange, P.; Boutin, J.A.; Renard, P.; Lesieur, D. Synthesis of Nitroindole
Derivatives with High Affinity and Selectivity for Melatoninergic Binding Sites MT3. J. Med.
Chem. 2002, 45, 1853–1859.
35. Yous, S.; Andrieux, J.; Howell, H.E.; Morgan, P.J.; Renard, P.; Pfeiffer, B.; Lessieur, D.;
Guardiola-Lemaitre, B. Novel naphthalenic ligands with high affinity for the melatonin receptor.
J. Med. Chem. 1992, 35, 1484–1486.
36. Assogba, L.; Ahamada-Himidi, A.; Meddad-Bel Habich, N.; Aoun, D.; Boukli, L.; Massicot, F.;
Mounier, C.M.; Huet, J.; Lamouri, A.; Ombetta, J.E.; et al. Inhibition ofsecretoryphospholipase A2.
Design, synthesis and structure–activity relationship studies starting from 4-tetradecyloxy-
benzamidine to obtain specific inhibitors of group II sPLA2s. Eur. J. Med. Chem. 2005, 40,
850–861.
37. Boukli, L.; Touaibia, M.; Meddad-Belhabich, N.; Djimdé, A.; Park, C.H.; Kim, J.J.; Yoon, J.H.;
Lamouri, A.; Heymans, F. Design of new potent and selective secretory phospholipase A2
inhibitors. Part 5: Synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-
5-one-3-ylmethylbenz-4′-yl(oyl)] piperazines. Bioorg. Med. Chem. 2008, 16, 1242–1253.
38. Lenda, F.; Guenoun, F.; Tazi, B.; Ben Larbi, N.; Allouchi, H.; Martinez, J.; Lamaty, F. Synthesis of
New Tetrazole-Substituted Pyroaminoadipic and Pipecolic Acid Derivatives. Eur. J. Org. Chem.
2005, 326–333.
39. McKay, A.F.; Braun, R.O. Cyclizationsof β-Chloroethyl Substituted Amminocarbonic Acids.
J. Org. Chem. 1951, 16, 1829–1832.
40. Depreux, P.; Lesieur, D.; Ait Mansour, H.; Morgan, P.; Howell, H.E.; Renard, P.; Caignard, D.H.;
Pfeiffer, B.; Delagrange, P.; Guardiola, B.; et al. Synthesis and Structure-Activity Relationships of
Novel Naphthalenic and Bioisosteric Related Amidic Derivatives as Melatonin Receptor Ligands.
J. Med. Chem. 1994, 37, 3231–3239.
41. Mésangeau, C.; Yous, S.; Pérèz, B.; Lesieur, D.; Besson, T. Pictet–Spengler heterocyclizations via
microwave-assisted degradation of DMSO. Tetrahedron Lett. 2005, 46, 2465–2468.
42. Dess, D.B.; Martin, J.C. Readily accessible 12-I-5 oxidant for the conversion of primary and
secondary alcohols to aldehydes and ketones. J. Org. Chem. 1983, 48, 4155–4156.
43. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint,
S.; Rodriguez, M.; Nagel, N.; Galizzi, J.P.; et al. New selective ligands of human cloned melatonin
MT1 and MT2 receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 2003, 36, 7553–7561.
Sample Availability: Samples of the compounds 5, 13, 14 and 15 are available from the authors.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).